ENTITY
Ocumension

Ocumension (1477 HK)

55
Analysis
Industrials • China
Ocumension is a China-based ophthalmic pharmaceutical platform company focused on discovering, developing, and commercializing first- or best-in-class ophthalmic therapies. Its product portfolio addresses various eye diseases, including uveitis, dry eye, glaucoma, and macular degeneration. The company was founded in 2017 and is headquartered in Suzhou, China.
more
bullish•Ocumension
•29 Jun 2020 16:48

Ocumension (欧康维视) IPO: Hot Deal, Small Float

Ocumension Therapeutics, a leading ophthalmic pharmaceutical platform company with a focus on first-in-class or best-in-class ophthalmic...

Logo
562 Views
Share
bullish•Ocumension
•28 Jun 2020 21:38

Ocumension Therapeutics IPO Initiation: Look into My Eyes

Ocumension Therapeutics (1764324D CH) is a China-based ophthalmic pharmaceutical company dedicated to identifying, developing and commercializing...

Logo
596 Views
Share
bullish•Ocumension
•22 Jun 2020 09:57

Ocumension (欧康维视) Pre-IPO: All Ready for a Great Listing Except a Block Buster

Ocumension Therapeutics, a leading ophthalmic pharmaceutical platform company with a focus on first-in-class or best-in-class ophthalmic therapies,...

Logo
703 Views
Share
x